astria therapeutics glp-1 receptor agonist weight management diabetes treatments Advances in agonists delivery systems for obesity and GLP-1 for Diabetes vs GLP-1

The role of tumor necrosis factor-alpha in the pathogenesis and treatment of nonalcoholic fatty liver disease

Orlistat-associated adverse effects and drug interactions

These broader changes could have a wide-ranging impact on companies across numerous sectors including healthcare, pharmaceuticals, insurers, medical device companies, the food and beverage industry, retailers, fitness businesses, airlines and many more

Preliminary research suggests it may influence incretin hormone pathways, though clinical evidence supporting meaningful GLP-1 or GIP enhancement in humans is lacking

Another GLP-1 analogue, exenatide, has also shown promising results against neurodegenerative diseases in a pre-clinical study (53)

Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure